Boulder Biotech Launch Specialists
A Redefined Approach to Life Science Launches

Innovation in biotech, including the development of novel cell and gene therapies, is transforming the treatment of many diseases. Most life-augmenting initiatives, however, miss out on the spotlight they deserve due to a lack of marketing expertise. Amid an increasingly competitive market (primarily due to the limited in-person provider access after COVID-19), biotech companies need a reliable partner to enhance product positioning and communications and accelerate launch readiness.

This is where Boulder Biotech Launch Specialists—a community of medical, regulatory, legal, sales, marketing, and market access experts with proven launch expertise— makes a world of difference. It accelerates the launch readiness and time-to-peak sales for advanced biologics, including cell and gene therapies and antibodies.

“Beginning early in clinical development, we help biotechnology companies drive strategic and operational launch readiness through robust product positioning and message development,” says Christopher Leidli, founder and managing partner, Boulder Biotech Launch Specialists.
Boulder Biotech Launch Specialists’ core competencies around product development, commercialization, business development, and portfolio strategy include branding, marketing and promotion, HCP influencer strategy, payer strategy, sales operations and training, value proposition refinement, landscape assessment, asset valuation, and due diligence.

Realization of the Market is the Key to Success Boulder

Biotech Launch Specialists also understands the go-to-market model for immuno-oncology therapeutics, like cell therapies, demands a redefined marketing approach due to the complex care coordination process entailing multi-disciplinary HCP coordination and patient referrals to treatment centers. Boulder Biotech Launch Specialists addresses this need by working with emerging and established pharma companies looking for process and quality improvements in the supply chain, manufacturing, and clinical development to enhance launch readiness.

“Regenerative medicines are inherently different from small prescription drugs, delivered through specialized treatment and academic centers. For these medicines, product and process characterization is essential to accelerate operational and strategic readiness for go-Boulder Biotech Launch Specialists A Redefined Approach to Life Science Launches Christopher Leidli, Founder and Managing Partner BIOTECH TOP 10 SERVICES COMPANIES - 2022 Life Sciences Marketing to-market,” says Leidli.

“The entire approach to onboarding, training, and educating HCPs, patients, payers, and academic treatment centers is different. It requires an experienced support team like we have built.”

For instance, Boulder Biotech Launch Specialists crafted a corporate communications strategy, digital and social media content, and an omnichannel publishing schedule to increase HCP awareness of a novel investigational T-cell therapy platform. In another instance, it counseled a mid-sized biotech company on commercial restructuring initiatives during COVID-19 that led to higher HCP engagement and delivered P&L impact.

The Comprehensive 360 Launch Accelerator Program

Boulder Biotech Launch Specialists works with clients through its proprietary 360 Launch Accelerator program, performing a 30-day Launch Readiness Diagnostic. It then recommends one of the four core pillars of its offerings: 360 Commercial Launch Accelerator, 360 Clinical Operations Launch Accelerator, 360 Operational Launch Readiness Accelerator, or 360 Cell Therapy Launch Readiness Accelerator.

Boulder Biotech Launch Specialists goes above and beyond as a marketing strategy consulting firm. The advisors come with extensive industry launch experience. This is a massive value proposition, given that hiring field teams and working on marketing and market access is an afterthought for most biotech companies. Boulder Biotech Launch Specialists renders its services via the traditional project-based contract or a flexible subscription-based approach.

In the latter, for a flat monthly fee, the company deploys virtual or on-site resources to add functional area expertise early—before commercial teams and FTEs are hired—in clinical development. It can also dispatch contract employees to help clients fill capability gaps and assist them with building marketing and launch infrastructure.

In the wake of the U.S. biotech scene rapidly evolving and diversifying, companies like Boulder Biotech Launch Specialists are indispensable partners for established and emerging biotech entities. Enabling biotech companies to do what they do best, it ensures the story and value of their initiatives get the recognition and resonance they deserve. After all, the patient wins when a product is launched optimally and when providers have access to novel therapeutics.

“The future will revolve around advanced biologics, cell and gene therapy. We want to establish a leadership position in this field and become a go-to resource that helps companies bring innovative medicines to market and benefit patients,” adds Leidli.

Leidli has also launched a podcast, Rx for Biotech, to take a deep dive into the biotech ecosystem. Industry leaders and disruptors share their insights and knowledge to inform biotech companies regarding the intricacies of cell and gene therapy and the importance of organizational launch readiness. The podcast holds immense importance for more than 650 cell and gene therapy developers in the U.S., and many new approvals that are expected over the next decade.